PDF(Pubmed)
Abstract：
UNASSIGNED: Asthma was initially described as a risk factor for severe coronavirus disease 2019 (COVID-19), but the uptake of COVID-19 vaccine among young adults with asthma is not well studied.
UNASSIGNED: The aims were to assess COVID-19 vaccine uptake among young adults in general and to explore potential determinants including sociodemographic factors and asthma.
UNASSIGNED: Participants from the population-based birth cohort BAMSE (Barn/Child, Allergy, Milieu, Stockholm, Epidemiology) were included: 4,064 in the study population, 3,064 in a follow-up at age 24 years, and 2,049 in a COVID-19 follow-up (mean age, 26.5 years). Asthma and asthma-associated characteristics were assessed through questionnaires and clinical data. Data on all COVID-19 vaccines registered between January 1, 2021, and February 15, 2023, were extracted from the National Vaccination Register.
UNASSIGNED: In the study population (n = 4,064), 53.9% had ≥3 COVID-19 vaccine doses registered. In the 24-year follow-up population (n = 3,064), vaccine uptake differed in relation to education (P < .001). Among the participants with university/college education, 65.7% had an uptake of ≥3 doses of vaccine, compared to 54.1% among the participants with elementary school/high school education. Participants with asthma had decreased odds of receiving ≥3 doses (adjusted odds ratio = 0.62; 95% confidence interval, 0.41-0.92) and ≥2 compared to peers without asthma. Those with uncontrolled disease also had decreased odds of receiving ≥3 doses (adjusted odds ratio = 0.30; 95% confidence interval, 0.13-0.66) and ≥2 compared to participants with controlled asthma.
UNASSIGNED: COVID-19 vaccine uptake among young adults is lower in individuals from households with lower socioeconomic status and among those with asthma, including uncontrolled asthma.
UNASSIGNED: The aims were to assess COVID-19 vaccine uptake among young adults in general and to explore potential determinants including sociodemographic factors and asthma.
UNASSIGNED: Participants from the population-based birth cohort BAMSE (Barn/Child, Allergy, Milieu, Stockholm, Epidemiology) were included: 4,064 in the study population, 3,064 in a follow-up at age 24 years, and 2,049 in a COVID-19 follow-up (mean age, 26.5 years). Asthma and asthma-associated characteristics were assessed through questionnaires and clinical data. Data on all COVID-19 vaccines registered between January 1, 2021, and February 15, 2023, were extracted from the National Vaccination Register.
UNASSIGNED: In the study population (n = 4,064), 53.9% had ≥3 COVID-19 vaccine doses registered. In the 24-year follow-up population (n = 3,064), vaccine uptake differed in relation to education (P < .001). Among the participants with university/college education, 65.7% had an uptake of ≥3 doses of vaccine, compared to 54.1% among the participants with elementary school/high school education. Participants with asthma had decreased odds of receiving ≥3 doses (adjusted odds ratio = 0.62; 95% confidence interval, 0.41-0.92) and ≥2 compared to peers without asthma. Those with uncontrolled disease also had decreased odds of receiving ≥3 doses (adjusted odds ratio = 0.30; 95% confidence interval, 0.13-0.66) and ≥2 compared to participants with controlled asthma.
UNASSIGNED: COVID-19 vaccine uptake among young adults is lower in individuals from households with lower socioeconomic status and among those with asthma, including uncontrolled asthma.
摘要：
■哮喘最初被描述为2019年严重冠状病毒病（COVID-19）的危险因素，但COVID-19疫苗在患有哮喘的年轻成年人中的摄取情况还没有得到很好的研究。
■目的是评估一般年轻人对COVID-19疫苗的吸收，并探索潜在的决定因素，包括社会人口统计学因素和哮喘。
■来自基于人口的出生队列BAMSE（谷仓/儿童，过敏,Milieu,斯德哥尔摩,流行病学）包括：研究人群中的4,064，3,064在24岁的随访中，和COVID-19随访中的2,049人(平均年龄，26.5年）。通过问卷调查和临床数据评估哮喘和哮喘相关特征。2021年1月1日至2023年2月15日之间注册的所有COVID-19疫苗的数据均来自国家疫苗接种登记册。
■在研究人群中（n=4,064），53.9%的人登记了≥3次COVID-19疫苗剂量。在24年随访人群中（n=3,064），疫苗接种与教育有关(P<.001)。在大学/学院教育的参与者中，65.7%的人接种了≥3剂疫苗，相比之下，接受小学/高中教育的参与者为54.1%。哮喘患者接受≥3次剂量的几率降低(调整后的比值比=0.62;95%置信区间,与无哮喘的同龄人相比，0.41-0.92）和≥2。那些疾病不受控制的患者接受≥3次剂量的几率也降低(调整后的优势比=0.30;95%置信区间,与哮喘控制的参与者相比，0.13-0.66）和≥2。
■社会经济地位较低的家庭和哮喘患者的年轻人对COVID-19疫苗的吸收较低，包括不受控制的哮喘。
■目的是评估一般年轻人对COVID-19疫苗的吸收，并探索潜在的决定因素，包括社会人口统计学因素和哮喘。
■来自基于人口的出生队列BAMSE（谷仓/儿童，过敏,Milieu,斯德哥尔摩,流行病学）包括：研究人群中的4,064，3,064在24岁的随访中，和COVID-19随访中的2,049人(平均年龄，26.5年）。通过问卷调查和临床数据评估哮喘和哮喘相关特征。2021年1月1日至2023年2月15日之间注册的所有COVID-19疫苗的数据均来自国家疫苗接种登记册。
■在研究人群中（n=4,064），53.9%的人登记了≥3次COVID-19疫苗剂量。在24年随访人群中（n=3,064），疫苗接种与教育有关(P<.001)。在大学/学院教育的参与者中，65.7%的人接种了≥3剂疫苗，相比之下，接受小学/高中教育的参与者为54.1%。哮喘患者接受≥3次剂量的几率降低(调整后的比值比=0.62;95%置信区间,与无哮喘的同龄人相比，0.41-0.92）和≥2。那些疾病不受控制的患者接受≥3次剂量的几率也降低(调整后的优势比=0.30;95%置信区间,与哮喘控制的参与者相比，0.13-0.66）和≥2。
■社会经济地位较低的家庭和哮喘患者的年轻人对COVID-19疫苗的吸收较低，包括不受控制的哮喘。
